Figure 4

VTX-2337 shows an anti-tumor effect in vivo. (A–C) C3H mice bearing SCCVII tumors (A), C57BL/6 mice bearing mEERL (B), and BALB/c mice bearing TUBO-hEGFR tumors (C) were treated with PBS (Control) or VTX-2337 (VTX) and tumor growth was measured. Arrow in (A) represents the time at which tumor growth in a control-treated mouse reached euthanasia criteria. N = 5–9 mice/treatment group. (D) VTX and cetuximab (CTX) treatment schema. (E–I) BALB/c mice (n = 10 mice/group, 5 male/5 female) bearing TUBO-hEGFR tumors were treated as in (D) with IgG + PBS used as controls. Separate tumor growth graphs are shown for male (F) and female (G) mice from E. Error bars represent standard error of the mean. (H–I) Shown are Kaplan Meier curves comparing overall and median survival of all mice (H) and CTX + VTX-treated mice from H separated into female and male (I). *p < 0.05. NS: non-significant (Linear regression).